Avid Bioservices Inc (CDMO)

[entdoc]

KT and Volgoat, regarding virtues of murine/humanized MAB Bavituximab, the most interesting thing I've seen is Volgoat's last post about binding site specificity decreasing with more fully humanized MAb Bavi. I can imagine that murine MAbs probably have a more general immunoexcitatory phase than murine too. The whole idea is to convert cancer into a chronic disease like diabetes so that patients can live productive lives while being "carriers". If Bavi can prevent growth of metastases as anticipated and can be used periodically for maintenence, it will be a true treatment advance.